Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. (KPTI) Revenue
Annual & quarterly revenue history · segment & region breakdown
KPTI · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsKaryopharm Therapeutics Inc. trailing twelve-month (TTM) revenue is $0.15B, an increase of 0.00% year-over-year from — in FY.
Revenue trend
– · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Karyopharm Therapeutics Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Karyopharm Therapeutics Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Karyopharm Therapeutics Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
KPTI revenue · 4 questionsKPTI's trailing twelve-month (TTM) revenue is $0.15B. That is an increase of 0.00% year-over-year from — in FY.
▸ Source: FMP · Karyopharm Therapeutics Inc. SEC filings · GAAP · Karyopharm Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026